{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:21:34Z","timestamp":1793157694314,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch","doi-asserted-by":"publisher","award":["114-BIH037"],"award-info":[{"award-number":["114-BIH037"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2314-B-002 -198 -"],"award-info":[{"award-number":["114-2314-B-002 -198 -"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s15010-026-02744-8","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:33:30Z","timestamp":1770482010000},"page":"1289-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical epidemiology, genospecies distribution, and in vitro susceptibility to novel agents among Burkholderia cepacia complex bloodstream infections in Taiwan"],"prefix":"10.1007","volume":"54","author":[{"given":"Szu-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"2744_CR1","unstructured":"Mandell, Douglas, Bennett. Principles and Practice of Infectious Diseases, Ninth Edition 2019."},{"key":"2744_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jinf.2018.07.006","volume":"77","author":"MM Sfeir","year":"2018","unstructured":"Sfeir MM. Burkholderia cepacia complex infections: more complex than the bacterium name suggest. J Infect. 2018;77:166\u201370.","journal-title":"J Infect"},{"key":"2744_CR3","first-page":"CD009529","volume":"2016","author":"A Horsley","year":"2016","unstructured":"Horsley A, Jones AM, Lord R. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. 2016;2016:CD009529.","journal-title":"Cochrane Database Syst Rev"},{"key":"2744_CR4","first-page":"299","volume":"26","author":"M Abdallah","year":"2018","unstructured":"Abdallah M, Abdallah HA, Memish ZA. Burkholderia cepacia complex outbreaks among non-cystic fibrosis patients in the intensive care units: a review of adult and pediatric literature. Infez Med. 2018;26:299\u2013307.","journal-title":"Infez Med"},{"key":"2744_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ajic.2021.10.028","volume":"50","author":"CC Eldridge","year":"2022","unstructured":"Eldridge CC, Flinchum AH, Thoroughman D, Spicer KB. A pseudo-outbreak of Burkholderia cepacia complex in a Kentucky hospital. Am J Infect Control. 2022;50:342\u20134.","journal-title":"Am J Infect Control"},{"key":"2744_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1017\/ice.2020.184","volume":"41","author":"RZ Shaban","year":"2020","unstructured":"Shaban RZ, Sotomayor-Castillo C, Nahidi S, Li C, Macbeth D, Mitchell BG, et al. Global burden, point sources, and outbreak management of healthcare-associated Burkholderia cepacia infections: an integrative review. Infect Control Hosp Epidemiol. 2020;41:777\u201383.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2744_CR7","doi-asserted-by":"publisher","first-page":"100039","DOI":"10.1016\/j.infpip.2020.100039","volume":"2","author":"E Lo Priore","year":"2020","unstructured":"Lo Priore E, Bernasconi S, Schlotterbeck H, Seth-Smith HM, Egli A, Martinetti G, et al. Burkholderia cepacia complex outbreak originating from contaminated wash gloves. Infect Prev Pract. 2020;2:100039.","journal-title":"Infect Prev Pract"},{"key":"2744_CR8","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1128\/JCM.43.6.2926-2928.2005","volume":"43","author":"R Reik","year":"2005","unstructured":"Reik R, Spilker T, Lipuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol. 2005;43:2926\u20138.","journal-title":"J Clin Microbiol"},{"key":"2744_CR9","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s10096-012-1707-6","volume":"31","author":"MJ Medina-Pascual","year":"2012","unstructured":"Medina-Pascual MJ, Valdezate S, Villalon P, Garrido N, Rubio V, Saez-Nieto JA. Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain. Eur J Clin Microbiol Infect Dis. 2012;31:3385\u201396.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2744_CR10","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1128\/JCM.01360-13","volume":"51","author":"KA Ramsay","year":"2013","unstructured":"Ramsay KA, Butler CA, Paynter S, Ware RS, Kidd TJ, Wainwright CE, et al. Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis. J Clin Microbiol. 2013;51:3975\u201380.","journal-title":"J Clin Microbiol"},{"key":"2744_CR11","first-page":"281","volume":"38","author":"A Lupo","year":"2015","unstructured":"Lupo A, Isis E, Tinguely R, Endimiani A. Clonality and antimicrobial susceptibility of Burkholderia cepacia complex isolates collected from cystic fibrosis patients during 1998-2013 in Bern, Switzerland. New Microbiol. 2015;38:281\u20138.","journal-title":"New Microbiol"},{"key":"2744_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijantimicag.2016.07.020","volume":"48","author":"FK Abbott","year":"2016","unstructured":"Abbott FK, Milne KE, Stead DA, Gould IM. Combination antimicrobial susceptibility testing of Burkholderia cepacia complex: significance of species. Int J Antimicrob Agents. 2016;48:521\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"2744_CR13","doi-asserted-by":"publisher","first-page":"e104986","DOI":"10.1371\/journal.pone.0104986","volume":"9","author":"SP Tseng","year":"2014","unstructured":"Tseng SP, Tsai WC, Liang CY, Lin YS, Huang JW, Chang CY, et al. The contribution of antibiotic resistance mechanisms in clinical Burkholderia cepacia complex isolates: an emphasis on efflux pump activity. PLoS ONE. 2014;9:e104986.","journal-title":"PLoS ONE"},{"key":"2744_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijantimicag.2017.07.004","volume":"51","author":"YC Chien","year":"2018","unstructured":"Chien YC, Liao CH, Sheng WH, Chien JY, Huang YT, Yu CJ, et al. Clinical characteristics of bacteraemia caused by Burkholderia cepacia complex species and antimicrobial susceptibility of the isolates in a medical centre in Taiwan. Int J Antimicrob Agents. 2018;51:357\u201364.","journal-title":"Int J Antimicrob Agents"},{"key":"2744_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.eimc.2017.09.002","volume":"36","author":"L Cipolla","year":"2018","unstructured":"Cipolla L, Rocca F, Martinez C, Aguerre L, Barrios R, Prieto M. Prevalence of Burkholderia cepacia complex species in cystic fibrosis patients in Argentina during the period 2011\u20132015. Enferm Infecc Microbiol Clin (Engl Ed). 2018;36:431\u20134.","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2744_CR16","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.ijmmb.2024.100613","volume":"49","author":"M Kumaresan","year":"2024","unstructured":"Kumaresan M, Manoharan M, Sugumar M, Sistla S. Species distribution and antimicrobial susceptibility of Burkholderia cepacia complex isolates in clinical infections: Experience from a tertiary care hospital. Southern India Indian J Med Microbiol. 2024;49:100613.","journal-title":"Southern India Indian J Med Microbiol"},{"key":"2744_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","volume":"28","author":"KA Rhodes","year":"2016","unstructured":"Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Updat. 2016;28:82\u201390.","journal-title":"Drug Resist Updat"},{"key":"2744_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.36519\/idcm.2023.259","volume":"5","author":"YE Ozdemir","year":"2023","unstructured":"Ozdemir YE, Kaplan-Yapar B, Borcak D, Canbolat-Unlu E, Bayramlar OF, Cizmeci Z, et al. Antimicrobial Susceptibility Profiles and Key Determinants for Mortality in Burkholderia cepacia Complex Infections. Infect Dis Clin Microbiol. 2023;5:239\u201350.","journal-title":"Infect Dis Clin Microbiol"},{"key":"2744_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jmii.2021.09.009","volume":"55","author":"TH Chang","year":"2022","unstructured":"Chang TH, Chuang YC, Wang JT, Sheng WH. Clinical characteristics and outcomes of non-cystic fibrosis patients with Burkholderia cepacia complex bacteremia at a medical center in Taiwan. J Microbiol Immunol Infect. 2022;55:1301\u20139.","journal-title":"J Microbiol Immunol Infect"},{"key":"2744_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/jac\/dky423","volume":"74","author":"C Massip","year":"2019","unstructured":"Massip C, Mathieu C, Gaudru C, Miaut V, Floch P, Oswald E, et al. In vitro activity of seven beta-lactams including ceftolozane\/tazobactam and ceftazidime\/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients. J Antimicrob Chemother. 2019;74:525\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2744_CR21","doi-asserted-by":"publisher","first-page":"e0034623","DOI":"10.1128\/aac.00346-23","volume":"67","author":"M Takemura","year":"2023","unstructured":"Takemura M, Nakamura R, Ota M, Nakai R, Sahm DF, Hackel MA, et al. In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrob Agents Chemother. 2023;67:e0034623.","journal-title":"Antimicrob Agents Chemother"},{"key":"2744_CR22","doi-asserted-by":"publisher","first-page":"dlae006","DOI":"10.1093\/jacamr\/dlae006","volume":"6","author":"YS Huang","year":"2024","unstructured":"Huang YS, Chuang YC, Chen PY, Chou PC, Wang JT. In vitro activity of cefiderocol and comparator antibiotics against multidrug-resistant non-fermenting Gram-negative bacilli. JAC Antimicrob Resist. 2024;6:dlae006.","journal-title":"JAC Antimicrob Resist."},{"key":"2744_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1476-0711-11-32","volume":"11","author":"GC Lee","year":"2012","unstructured":"Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012;11:32.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2744_CR24","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/AAC.02166-13","volume":"58","author":"GL Daikos","year":"2014","unstructured":"Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2744_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","volume":"55","author":"M Tumbarello","year":"2012","unstructured":"Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943\u201350.","journal-title":"Clin Infect Dis"},{"key":"2744_CR26","unstructured":"CDC. Healthcare-Associated Infections Access Date: 2025\/04\/18 [Available from: https:\/\/www.cdc.gov\/healthcare-associated-infections\/about\/index.html."},{"key":"2744_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1099\/jmm.0.019844-0","volume":"59","author":"MC Papaleo","year":"2010","unstructured":"Papaleo MC, Perrin E, Maida I, Fondi M, Fani R, Vandamme P. Identification of species of the Burkholderia cepacia complex by sequence analysis of the hisA gene. J Med Microbiol. 2010;59:1163\u201370.","journal-title":"J Med Microbiol"},{"key":"2744_CR28","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing 2024."},{"key":"2744_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","volume":"42","author":"MG Wise","year":"2023","unstructured":"Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023;42:1135\u201343.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2744_CR30","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1128\/JCM.00001-14","volume":"52","author":"D Marchaim","year":"2014","unstructured":"Marchaim D, Pogue JM, Tzuman O, Hayakawa K, Lephart PR, Salimnia H, et al. Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J Clin Microbiol. 2014;52:1617\u201321.","journal-title":"J Clin Microbiol"},{"key":"2744_CR31","doi-asserted-by":"publisher","first-page":"e0252724","DOI":"10.1128\/spectrum.02527-24","volume":"13","author":"S Ray","year":"2025","unstructured":"Ray S, Flemming LK, Scudder CJ, Ly MA, Porterfield HS, Smith RD, et al. Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing. Microbiol Spectr. 2025;13:e0252724.","journal-title":"Microbiol Spectr"},{"key":"2744_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40121-024-01099-7","volume":"14","author":"H Wang","year":"2025","unstructured":"Wang H, Li S, Ji H, Hu Y, Zhou S, Chen X, et al. Epidemiology and antimicrobial resistance of Stenotrophomonas maltophilia in China, 2014\u20132021. Infect Dis Ther. 2025;14:261\u201374.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"2744_CR33","doi-asserted-by":"publisher","first-page":"001882","DOI":"10.1099\/jmm.0.001882","volume":"73","author":"A Tozluyurt","year":"2024","unstructured":"Tozluyurt A. Molecular typing of reduced susceptibility of Acinetobacter calcoaceticus-baumannii complex to Chlorhexidine in Turkey by pulsed-field gel electrophoresis. J Med Microbiol. 2024;73(8):001882.","journal-title":"J Med Microbiol"},{"key":"2744_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1469-0691.2010.03237.x","volume":"16","author":"P Drevinek","year":"2010","unstructured":"Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16:821\u201330.","journal-title":"Clin Microbiol Infect"},{"key":"2744_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12348-021-00242-6","volume":"11","author":"C Lind","year":"2021","unstructured":"Lind C, Olsen K, Angelsen NK, Krefting EA, Fossen K, Gravningen K, et al. Clinical course, treatment and visual outcome of an outbreak of Burkholderia contaminans endophthalmitis following cataract surgery. J Ophthalmic Inflamm Infect. 2021;11:12.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2744_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijmmb.2020.10.023","volume":"39","author":"M Murugesan","year":"2021","unstructured":"Murugesan M, Ranjan J, Devanga Ragupathi NK, Michael JS, Viggeswarpu S, Wilson BP, et al. Diagnostic methods and identification challenges experienced in a Burkholderia contaminans outbreak occurred in a tertiary care centre. Indian J Med Microbiol. 2021;39:192\u20135.","journal-title":"Indian J Med Microbiol"},{"key":"2744_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/cid\/cix559","volume":"65","author":"NG El Chakhtoura","year":"2017","unstructured":"El Chakhtoura NG, Saade E, Wilson BM, Perez F, Papp-Wallace KM, Bonomo RA. A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States Veterans Health Administration. Clin Infect Dis. 2017;65:1253\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2744_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01194-20","volume":"65","author":"CA Pybus","year":"2021","unstructured":"Pybus CA, Felder-Scott C, Obuekwe V, Greenberg DE. Cefiderocol retains antibiofilm activity in multidrug-resistant gram-negative pathogens. Antimicrob Agents Chemother. 2021;65(2):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"key":"2744_CR39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","volume":"3","author":"KM Papp-Wallace","year":"2017","unstructured":"Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502\u201311.","journal-title":"ACS Infect Dis"},{"key":"2744_CR40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/mdr.2021.0353","volume":"28","author":"F Schaumburg","year":"2022","unstructured":"Schaumburg F, Idelevich EA, Mellmann A, Kahl BC. Susceptibility of Burkholderia cepacia complex to ceftazidime\/avibactam and standard drugs of treatment for cystic fibrosis patients. Microb Drug Resist. 2022;28:545\u201350.","journal-title":"Microb Drug Resist"},{"key":"2744_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-17","author":"DM Mazer","year":"2017","unstructured":"Mazer DM, Young C, Kalikin LM, Spilker T, LiPuma JJ. In vitro activity of ceftolozane-tazobactam and other antimicrobial agents against Burkholderia cepacia complex and Burkholderia gladioli. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00766-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2744_CR42","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s10096-020-03960-2","volume":"39","author":"YM Lee","year":"2020","unstructured":"Lee YM, Park KH, Moon C, Kim DY, Lee MS, Kim T, et al. Management and outcomes of Burkholderia cepacia complex bacteremia in patients without cystic fibrosis: a retrospective observational study. Eur J Clin Microbiol Infect Dis. 2020;39:2057\u201364.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2744_CR43","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1128\/AAC.00954-06","volume":"51","author":"J Zhou","year":"2007","unstructured":"Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2007;51:1085\u20138.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02744-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:43:35Z","timestamp":1782920615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2744"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02744-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of National Taiwan University Hospital (IRB No.: 202310108RINC) and informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}